Vaxzevria (previously COVID-19 Vaccine AstraZeneca)


COVID-19 Vaccine (ChAdOx1-S [recombinant])

This medicine is authorised for use in the European Union.


Vaxzevria is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older.

Vaxzevria is made up of another virus (of the adenovirus family) that has been modified to contain the gene for making a protein from SARS-CoV-2, the virus that causes COVID-19.

Vaxzevria does not contain the virus itself and cannot cause COVID-19.

This EPAR was last updated on 21/09/2023

Authorisation details

Product details
Vaxzevria (previously COVID-19 Vaccine AstraZeneca)
Agency product number
Active substance
International non-proprietary name (INN) or common name
COVID-19 Vaccine (ChAdOx1-S [recombinant])
Therapeutic area (MeSH)
COVID-19 virus infection
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
AstraZeneca AB
Date of issue of marketing authorisation valid throughout the European Union
Contact address

151 85 Sodertalje

Product information

15/09/2023 Vaxzevria (previously COVID-19 Vaccine AstraZeneca) - EMEA/H/C/005675 - PSUSA/00010912/202212

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Vaxzevria is indicated for active immunisation to prevent COVID 19 caused by SARS CoV 2, in individuals 18 years of age and older.

The use of this vaccine should be in accordance with official recommendations.

Assessment history

Changes since initial authorisation of medicine

Safety updates


Related content

How useful was this page?

Add your rating
110 ratings
59 ratings
31 ratings
31 ratings
101 ratings